Curated News
By: NewsRamp Editorial Staff
November 17, 2025

TransCode Appoints Oncology Veteran to Advance RNA Cancer Therapeutics

Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • TransCode Therapeutics gains strategic advantage by appointing Dr. Michel Janicot, leveraging his 35+ years of oncology expertise to accelerate TTX-MC138 and Seviprotimut-L toward clinical trials.
  • Dr. Janicot will guide TransCode's R&D strategy using his RNA biology and translational medicine expertise to advance oncology programs through preclinical and early clinical development stages.
  • This appointment strengthens TransCode's mission to defeat metastatic cancer through innovative RNA therapeutics, potentially improving treatment outcomes for cancer patients worldwide.
  • TransCode brings on a former Janssen leader with deep RNA expertise to advance their nanoparticle platform targeting microRNA-10b, a unique biomarker of cancer metastasis.

Impact - Why it Matters

This appointment signals accelerated development of potentially groundbreaking RNA-based cancer treatments that could transform metastatic cancer care. For patients facing metastatic disease—often considered the most challenging stage of cancer—TransCode's approach represents hope for new therapeutic options where conventional treatments frequently fail. The company's focus on targeting specific metastasis biomarkers like microRNA-10b could lead to more precise, effective treatments with fewer side effects. For the broader oncology field, successful development of RNA therapeutics could open entirely new avenues for cancer treatment, potentially making previously untreatable cancers manageable. Investors should note that experienced leadership in drug development significantly increases the likelihood of successfully navigating the complex clinical trial process and bringing innovative therapies to market.

Summary

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage oncology company focused on treating metastatic disease, has significantly strengthened its leadership team with the appointment of Dr. Michel Janicot as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of global oncology drug-development experience to TransCode, having previously served in senior leadership roles at major pharmaceutical companies including Rhône-Poulenc Rorer and Janssen. As the founder of JMi ONConsulting, he possesses deep expertise in RNA biology, preclinical strategy, translational medicine, and early clinical development that will be crucial for advancing TransCode's investigational oncology programs toward later-stage clinical trials. His appointment represents a strategic move to accelerate the development of the company's promising RNA therapeutics pipeline.

The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode's proprietary TTX nanoparticle platform is designed to overcome the challenges of RNA delivery, potentially unlocking access to novel genetic targets relevant to treating various cancers. The company's commitment to defeating cancer through intelligent design and effective delivery of RNA therapeutics positions it at the forefront of oncology innovation. For investors seeking comprehensive information, the Investor Intelligence Business Intelligence platform provides detailed coverage of TransCode's developments and strategic moves within the dynamic biopharmaceutical landscape.

InvestorWire, as part of the Dynamic Brand Portfolio managed by IBN, serves as the specialized communications platform distributing this announcement through its advanced wire-grade press release syndication services. The platform offers extensive distribution capabilities including article and editorial syndication to over 5,000 outlets, enhanced press release optimization, and comprehensive social media distribution through IBN's vast network. This ensures that news about TransCode's strategic appointments and pipeline developments reaches a wide audience of investors, journalists, and industry professionals efficiently and effectively, supporting the company's visibility within the investment community and broader healthcare sector.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Appoints Oncology Veteran to Advance RNA Cancer Therapeutics

blockchain registration record for this content.